脉冲性皮质类药物治疗可以降低患有遗传耐药性的儿童的间脉性活动负担
Katharina Schiller1,2,3, John Thomas1, Tamir Avigdor1
1Analytical Neurophysiology Lab, Department of Neurology and Neurosurgery, Montreal Neurological Hospital and Institute, Montreal, Quebec, Canada.
Epilepsia open
|June 4, 2024
概括
脉冲性皮质类药物治疗 (PCT) 显著降低了药物耐药的儿童中脉冲性活动负担. 这种治疗也改善了睡眠旋转率和生活质量,提供了潜在的新治疗途径.
科学领域:
- 儿科神经学 儿科神经学
- 发病学 (Epileptology) 是一个专业的学科.
- 药理学 药理学是指药理学的学科.
背景情况:
- 皮质类固醇和 adrenocorticotropic 激素 (ACTH) 是婴儿的标准,但在其他儿童中研究较少.
- ACTH 携带严重副作用的风险.
- 关于皮质类固醇在遗传性,抗药性儿童的疗效的数据有限.
研究的目的:
- 评估标准化脉冲性皮质类药物治疗 (PCT) 协议对患有遗传耐药性的儿童间脉冲性活动 (IEA) 负担的影响.
- 评估二次结果,包括睡眠旋转率,发作频率和生活质量.
主要方法:
- 一组24名患有耐药性的儿童接受了使用高剂量静脉注射德甲的标准PCT.
- 脑电图 (EEG) 记录在基线和治疗周期期间得到.
- 在PCT之前和之后,IEA负担,睡眠旋转率和发作频率进行了比较.
主要成果:
- 通过PCT显著降低了IEA的负担 (基线:5.4%与PCT后的1.5%,p=0.001).
- 睡眠旋转率显著增加 (p=0.045),表明睡眠生理有所改善.
- 71%的患者经历了发作频率的降低,大多数患者报告生活质量和睡眠的改善. 没有发现严重的不良影响.
结论:
- PCT有效地减少了IEA对患有遗传耐药性的儿童的负担.
- PCT改善了睡眠生理学,通过增加睡眠旋转率证明了这一点.
- 这些发现支持皮质类固醇在治疗儿科耐药性的潜在扩大.
相关概念视频
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
236
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
236
01:24Arteries of the Lower Limbs
188
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
188
01:30Electroconvulsive Therapy
33
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
33
01:17Antiepileptic Drugs: Calcium Channel Blockers
371
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
371
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
286
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
286
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
385
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
385